Zacks: vTv Therapeutics Inc. (VTVT) Given $18.75 Consensus Target Price by Analysts
Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus target price of $18.75 for the company and are anticipating that the company will post ($0.42) earnings per share for the current quarter, according to Zacks. Zacks has also assigned vTv Therapeutics an industry rank of 109 out of 265 based on the ratings given to its competitors.
A number of research analysts recently commented on the stock. Canaccord Genuity reiterated a “buy” rating and set a $15.00 price objective on shares of vTv Therapeutics in a research note on Friday, August 19th. Zacks Investment Research lowered shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, HC Wainwright assumed coverage on shares of vTv Therapeutics in a research note on Monday, September 26th. They set a “buy” rating and a $13.00 price objective on the stock.
Shares of vTv Therapeutics (NASDAQ:VTVT) traded up 0.786% during trading on Wednesday, reaching $6.924. The company’s stock had a trading volume of 3,543 shares. vTv Therapeutics has a 52 week low of $4.84 and a 52 week high of $8.22. The company has a 50 day moving average price of $6.46 and a 200 day moving average price of $5.91. The firm’s market capitalization is $67.09 million.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, August 16th. The company reported ($0.47) EPS for the quarter. On average, equities research analysts expect that vTv Therapeutics will post ($1.61) EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of the company. State Street Corp boosted its stake in shares of vTv Therapeutics by 10.9% in the first quarter. State Street Corp now owns 61,239 shares of the company’s stock worth $316,000 after buying an additional 6,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of vTv Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 34,884 shares of the company’s stock worth $180,000 after buying an additional 822 shares during the last quarter. Kennedy Capital Management Inc. acquired a new stake in shares of vTv Therapeutics during the first quarter worth $282,000. Ameriprise Financial Inc. boosted its stake in shares of vTv Therapeutics by 17.2% in the second quarter. Ameriprise Financial Inc. now owns 161,484 shares of the company’s stock worth $936,000 after buying an additional 23,705 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of vTv Therapeutics by 4.1% in the second quarter. Vanguard Group Inc. now owns 288,146 shares of the company’s stock worth $1,671,000 after buying an additional 11,428 shares during the last quarter. Hedge funds and other institutional investors own 12.84% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.